Tag Archive for: Cancer

Ariceum Therapeutics and NorthStar Medical Radioisotopes Announce Supply Agreement for Therapeutic Radioisotope Actinium-225

NorthStar will supply non-carrier added Actinium-225, a radionuclide, for use with Ariceum’s first-in-class radiopharmaceutical drug, satoreotide Berlin, Germany, and Beloit, Wisconsin, 11 December 2024 – Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization […]

Poolbeg Pharma plc presents POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting

All doses of POLB 001 significantly reduced clinically observed Cytokine Release Syndrome scores POLB 001 treatment showed statistically significant reductions in key cytokines  Positive results reinforce the use case for POLB 001 in the prevention and treatment of cancer immunotherapy-induced CRS 9 December 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focused […]

Optimum’s hot topic: Can we ‘bottle’ the remarkable biology of people who, against all odds, beat killer diseases?

By Stephen Adams, Optimum Strategic Communications   Nature has been an inspiration behind the development of many drugs, starting with the humble aspirin, which was originally derived from willow bark.  But what if we could learn the secrets of what gives some people the incredible ability to overcome the most serious diseases?  What if we could […]

Ariceum Therapeutics and Eckert & Ziegler Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments

Berlin, Germany, December 5, 2024 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and Eckert & Ziegler, one of the world’s largest providers of isotopes for medical, scientific and industrial use, today announced the signing of a global supply agreement for the medical radionuclides […]

Cure51 launches NHS-approved study with Cambridge University Hospitals and seven other leading UK oncology institutions to unlock cancer survival secrets

Pioneering Rosalind study aims to transform cancer treatment with insights from ‘super-responder’ patients Tumor samples from over 1,000 cancer survivors across three aggressive types will be analyzed for genetics and biomarkers Findings will enrich Cure51’s multi-omics database to advance new biology and precision medicine tools Paris, France, 18 November 2024 – Cure51, a techbio company […]

© Optimum Strategic Communications.